Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) announced that it underwent a cGMP (Current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration (FDA) from August 4 to August 7, 2025. The inspection covered six major systems: quality management, materials, production, packaging and labeling, facilities and equipment, and laboratory controls. Recently, the company confirmed via the FDA's official website that it has successfully passed the inspection, demonstrating compliance with the FDA's cGMP standards.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments